UNIVERSITY OF WASHINGTON

- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 1861-01-01
- Employees
- 10K
- Market Cap
- -
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
- Conditions
- Adult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Neoplasm
- Interventions
- Other: Quality-of-Life Assessment
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 45
- Registration Number
- NCT00823797
- Locations
- πΊπΈ
Northwestern University, Chicago, Illinois, United States
πΊπΈHuntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
πΊπΈFred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
- Conditions
- Skin MetastasesRecurrent Breast CancerMale Breast CancerStage IV Breast Cancer
- Interventions
- Other: laboratory biomarker analysisGenetic: RNA analysisOther: immunoenzyme technique
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2018-01-02
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 15
- Registration Number
- NCT00821964
- Locations
- πΊπΈ
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Immunomodulation Following Transfusion
- Conditions
- Blood Component Transfusion
- Interventions
- Biological: Standard blood componentsBiological: Leukoreduced blood componentsBiological: Leukoreduced and irradiated
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 287
- Registration Number
- NCT00810810
- Locations
- πΊπΈ
Northwest Hospital, Seattle, Washington, United States
πΊπΈUniversity of Washington Medical Center, Seattle, Washington, United States
Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill
- Conditions
- Major Depressive DisorderDrug AbuseBipolar DisorderSchizophrenia
- Interventions
- Behavioral: Contingency ManagementBehavioral: Non Contingent Control Condition
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 176
- Registration Number
- NCT00809770
- Locations
- πΊπΈ
Harborview Medical Center, Seattle, Washington, United States
GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 88
- Registration Number
- NCT00808405
- Locations
- πΏπ¦
Reproductive Health and HIV Research Unit (RHRU), Johannesburg, South Africa
πΏπ²Center for Infectious Disease Research of Zambia (CIDRZ), Lusaka, Zambia
Prediction of Post-Cesarean Section Pain
- Conditions
- Postoperative Pain
- Interventions
- Other: Psychophysical testing, questionnaires, and genetics
- First Posted Date
- 2008-11-27
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 800
- Registration Number
- NCT00799162
- Locations
- πΊπΈ
Stanford University, Stanford, California, United States
πΊπΈUniversity of Washington, Seattle, Washington, United States
π§πͺSt. Luc Hospital, University Catholic of Louvain, Brussels, Belgium
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
- Conditions
- HER2-positive Breast CancerMale Breast CancerRecurrent Breast CancerStage IV Breast Cancer
- Interventions
- Biological: HER-2/neu peptide vaccineProcedure: leukapheresisBiological: ex vivo-expanded HER2-specific T cellsBiological: sargramostimOther: laboratory biomarker analysis
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 23
- Registration Number
- NCT00791037
- Locations
- πΊπΈ
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
- Conditions
- Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver Cancer
- Interventions
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 41
- Registration Number
- NCT00787787
- Locations
- πΊπΈ
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Study of Paraesophageal Hernia Repair With Small Intestine Submucosa
- Conditions
- Hiatal HerniaParaesophageal Hernia
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2009-10-01
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 108
- Registration Number
- NCT00786084
- Locations
- πΊπΈ
Washington University School of Medicine, St Louis, Missouri, United States
πΊπΈOregon Health & Science University, Portland, Oregon, United States
πΊπΈThe Oregon Clinic, PC, Portland, Oregon, United States
Validating PROMIS Instruments in Back and Leg Pain
- Conditions
- Leg PainBack Pain
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 226
- Registration Number
- NCT00784251
- Locations
- πΊπΈ
Harborview Medical Center, Seattle, Washington, United States
πΊπΈUWMC Sports and Spine Physicians, Seattle, Washington, United States